Filing Flows › Pacira BioSciences (PCRX) › Q1 2025
Pacira BioSciences (PCRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Pacira BioSciences (PCRX) reported revenue of $169M for the first quarter 2025 (Q1 2025), +1% from a year earlier and -10% from the quarter before. Operating margin was 1.2%, net earnings $4.8M (2.8% of revenue).
Pacira BioSciences, Q1 2025: revenue $169M (+1% year over year), operating margin 1.2%, net earnings $4.8M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $169M | -10% | +1% |
| Operating profit | $2.0M | -92% | -85% |
| Net earnings | $4.8M | -70% | -46% |
| Operating cash flow | $35.5M | +7% | -28% |
| Free cash flow | $26.9M | -13% | -42% |
What changed
Revenue was $168.9M in Q1 2025, up 1% year over year and down 10% from the previous quarter. EXPAREL was the largest line at 81% of revenue. EXPAREL added $4.1M year over year (up 3%), 227% of the total change. ZILRETTA declined 10%.
Operating profit was $2.0M, a 1.2% margin (down 6.7 points year over year). Operating profit fell $11.2M even though revenue rose $1.8M versus a year earlier, so costs grew faster than sales. Total costs grew 8% against revenue growth of 1%. The fastest-growing cost line was Research & development (+39%). Net earnings were $4.8M, down 46% year over year. The effective tax rate was 44.7%. Non-operating items added $6.7M, 77% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $35.5M (down 28% year over year), 737% of net earnings. Non-cash charges added back $21.2M of depreciation and amortization and $14.6M of share-based compensation. Working capital and other items used $5.1M. Capital expenditures of $8.5M left free cash flow of $26.9M.
Questions
What was Pacira BioSciences' revenue in the first quarter 2025?
Pacira BioSciences (PCRX) reported revenue of $169M for the first quarter 2025 (Q1 2025), +1% from a year earlier and -10% from the quarter before.
Was Pacira BioSciences profitable in the first quarter 2025?
Operating profit was $2.0M (1.2% of revenue) and net earnings $4.8M.
Source: Pacira BioSciences 10-Q on SEC EDGAR.